Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer-Reference-Cited by-同舟云学术

Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer

Published:2015-05-16 Issue:3 Volume:151 Page:709-715
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Soysal Savas D.,Kilic Incken B.,Regenbrecht Christian R. A.,Schneider Sandra,Muenst Simone,Kilic Nerbil,Güth Uwe,Dietel Manfred,Terracciano Luigi M.,Kilic Ergin

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-015-3427-y.pdf

Reference20 articles.

1. Adelaide J, Finetti P, Charafe-Jauffret E, Wicinski J, Jacquemier J, Sotiriou C, Bertucci F, Birnbaum D, Chaffanet M (2008) Absence of ESR1 amplification in a series of breast cancers. Int J Cancer 123:2970–2972

2. Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, Chin K, Teschendorff AE, Quackenbush JF, Marioni JC, Leung S, Perou CM, Neilsen TO, Ellis M, Gray JW, Bernard PS, Huntsman DG, Caldas C (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:806–807 (author reply 810-802)

3. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151. doi: 10.1056/NEJM198501173120303

4. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ III, Visscher DW (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353:229–237

5. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers;Communications Biology;2022-04-19

2. Effect of exemestane endocrine therapy for hormone-receptor-positive breast cancer patients with varying levels of ctDNA;TROP J PHARM RES;2021

3. Somatic genetic aberrations in benign breast disease and the risk of subsequent breast cancer;npj Breast Cancer;2020-06-12

4. GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers;2020-05-20

5. Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients;Frontiers in Medicine;2019-07-24